Protection against anthrax and plague by a combined vaccine in mice and rabbits

Vaccine

Volumn 27, Issue 52, 2009, Pages 7436-7441

  Ren, Jun ^a   Dong, Dayong ^a   Zhang, Jinlong ^a   Zhang, Jun ^a   Liu, Shuling ^a   Li, Bing ^a   Fu, Ling ^a   Xu, Junjie ^a   Yu, Changming ^a   Hou, Lihua ^a   Li, Jianmin ^a   Chen, Wei ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Anthrax; Combined vaccine; Plague

Indexed keywords

ALUMINUM HYDROXIDE; BACILLUS ANTHRACIS ANTIGEN; BACTERIAL ANTIGEN; FRACTION 1 CAPSULAR ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; UNCLASSIFIED DRUG; V ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; ARTICLE; BACILLUS ANTHRACIS; DRUG FORMULATION; FEMALE; MOUSE; NONHUMAN; PLAGUE; PRIORITY JOURNAL; RABBIT; YERSINIA PESTIS;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MOLECULAR CHAPERONES; NEUTRALIZATION TESTS; PLAGUE; PLAGUE VACCINE; RABBITS; VACCINES, COMBINED;

EID: 70649091138     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.015     Document Type: Article

References (40)

1. Lane H.C., Montagne J.L., and Fauci A.S. Bioterrorism: a clear and present danger. Nature Medicine 7 December (12) (2001) 1271-1273
2. Brey R.N. Molecular basis for improved anthrax vaccines. Advanced Drug Delivery Reviews 57 June (9) (2005) 1266-1292
3. Collier R.J., and Young J.A. Anthrax toxin. Annual Review of Cell and Developmental Biology 19 (2003) 45-70
4. Bradley K.A., Mogridge J., Mourez M., Collier R.J., and Young J.A. Identification of the cellular receptor for anthrax toxin. Nature 414 November (6860) (2001) 225-229
5. Scobie H.M., Rainey G.J., Bradley K.A., and Young J.A. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proceedings of the National Academy of Sciences of the United States of America 100 April (9) (2003) 5170-5174
6. Perry R.D., and Fetherston J.D. Yersinia pestis-etiologic agent of plague. Clinical Microbiology Reviews 10 January (1) (1997) 35-66
7. Prentice M.B., and Rahalison L. Plague. Lancet 369 April (9568) (2007) 1196-1207
8. Mueller C.A., Broz P., Müller S.A., Ringler P., Erne-Brand F., Sorg I., et al. The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles. Science 310 October (5748) (2005) 674-676
9. Sing A., Rost D., Tvardovskaia N., Roggenkamp A., Wiedemann A., Kirschning C.J., et al. Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. The Journal of Experimental Medicine 196 October (8) (2002) 1017-1024
10. Du Y., Rosqvist R., and Forsberg A. Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infection and Immunity 70 March (3) (2002) 1453-1460
11. Anderson Jr. G.W., Leary S.E., Williamson E.D., Titball R.W., Welkos S.L., Worsham P.L., et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infection and Immunity 64 November (11) (1996) 4580-4585
12. Jernigan J.A., Stephens D.S., Ashford D.A., Omenaca C., Topiel M.S., Galbraith M., et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerging Infectious Diseases 7 November-December (6) (2001) 933-944
13. Li B., Jiang L., Song Q., Yang J., Chen Z., Guo Z., et al. Protein microarray for profiling antibody responses to Yersinia pestis live vaccine. Infection and immunity 73 June (6) (2005) 3734-3739
14. Turnbull P.C. Anthrax vaccines: past, present and future. Vaccine 9 August (8) (1991) 533-539
15. Russell P., Eley S.M., Hibbs S.E., Manchee R.J., Stagg A.J., and Titball R.W. A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 13 November (16) (1995) 1551-1556
16. Ivins B.E., Pitt M.L., Fellows P.F., Farchaus J.W., Benner G.E., Waag D.M., et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16 July (11-12) (1998) 1141-1148
17. Little S.F., Ivins B.E., Webster W.M., Fellows P.F., Pitt M.L., Norris S.L., et al. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 24 March (14) (2006) 2530-2536
18. McBride B.W., Mogg A., Telfer J.L., Lever M.S., Miller J., Turnbull P.C., et al. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 16 May (8) (1998) 810-817
19. Singh Y., Ivins B.E., and Leppla S.H. Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis. Infection and Immunity 66 July (7) (1998) 3447-3448
20. Williamson E.D., Hodgson I., Walker N.J., Topping A.W., Duchars M.G., Mott J.M., et al. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infection and Immunity 73 September (9) (2005) 5978-5987
21. Anderson Jr. G.W., Heath D.G., Bolt C.R., Welkos S.L., and Friedlander A.M. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. The American Journal of Tropical Medicine and Hygiene 58 June (6) (1998) 793-799
22. Jones S.M., Griffin K.F., Hodgson I., and Williamson E.D. Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine 21 September (25-26) (2003) 3912-3918
23. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., and Titball R.W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 15 July (10) (1997) 1079-1084
24. Williamson E.D., Flick-Smith H.C., Waters E., Miller J., Hodgson I., Le Butt C.S., et al. Immunogenicity of the rF1 + rV vaccine for plague with identification of potential immune correlates. Microbial Pathogenesis 42 January (1) (2007) 11-21
25. Williamson E.D., Stagg A.J., Eley S.M., Taylor R., Green M., Jones S.M., et al. Kinetics of the immune response to the (F1 + V) vaccine in models of bubonic and pneumonic plague. Vaccine 25 January (6) (2007) 1142-1148
26. Gorse G.J., Keitel W., Keyserling H., Taylor D.N., Lock M., Alves K., et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 24 August (33-34) (2006) 5950-5959
27. Williamson E.D., Flick-Smith H.C., Lebutt C., Rowland C.A., Jones S.M., Waters E.L., et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infection and Immunity 73 June (6) (2005) 3598-3608
28. li J., Li B., Li G., Ren J., Zhang J., Xu C., et al. Design and preparation of non-tagged Yersinia pestis LcrV antigen in Escherichia coli and its immunogenicity in BALB/c mice. Protein Expression and Purification 57 February (2) (2008) 136-142
29. Xu J.J., Dong D.Y., Song X.H., Ge M., Li G.L., Fu L., et al. Expression, purification and characterization of the recombinant anthrax protective antigen. Sheng Wu Gong Cheng Xue Bao (Chinese Journal of Biotechnology) 20 September (5) (2004) 652-655
30. Yin Y., Zhang J., Dong D., Liu S., Guo Q., Song X., et al. Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis. Vaccine 26 October (46) (2008) 5814-5821
31. Guo Q., Xu J.J., Dong D.Y., Fu L., and Chen W. Expression and characterization of the recombination anthrax lethal factor. Wei Sheng Wu Xue Bao (Acta Microbiologica Sinica) 44 December (6) (2004) 749-751
32. Andrews G.P., Heath D.G., Anderson Jr. G.W., Welkos S.L., and Friedlander A.M. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infection and Immunity 64 June (6) (1996) 2180-2187
33. Little S.F., Leppla S.H., and Friedlander A.M. Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infection and Immunity 58 June (6) (1990) 1606-1613
34. Williamson E.D., Vesey P.M., Gillhespy K.J., Eley S.M., Green M., and Titball R.W. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clinical and Experimental Immunology 116 April (1) (1999) 107-114
35. DuBois A.B., Freytag L.C., and Clements J.D. Evaluation of combinatorial vaccines against anthrax and plague in a murine model. Vaccine 25 June (24) (2007) 4747-4754
36. Griffin K., Bedford R., Townson K., Phillpotts R., Funnell S., Morton M., et al. Protective efficacy of a recombinant plague vaccine when co-administered with another sub-unit or live attenuated vaccine. FEMS Immunology and Medical Microbiology 43 March (3) (2005) 425-430
37. Mohamed N., Li J., Ferreira C.S., Little S.F., Friedlander A.M., Spitalny G.L., et al. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infection and Immunity 72 June (6) (2004) 3276-3283
38. Little S.F., Ivins B.E., Fellows P.F., Pitt M.L., Norris S.L., and Andrews G.P. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22 January (3-4) (2004) 422-430
39. Peachman K.K., Rao M., Alving C.R., Burge R., Leppla S.H., Rao V.B., et al. Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen. Infection and Immunity 74 January (1) (2006) 794-797
40. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infection and Immunity 69 May (5) (2001) 2888-2893